Diaceutics PLC (DXRX) - Net Assets
Based on the latest financial reports, Diaceutics PLC (DXRX) has net assets worth GBX40.48 Million GBX (≈ $4.93K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX50.01 Million ≈ $6.08K USD) and total liabilities (GBX9.53 Million ≈ $1.16K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Diaceutics PLC PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX40.48 Million |
| % of Total Assets | 80.95% |
| Annual Growth Rate | 73.18% |
| 5-Year Change | -0.42% |
| 10-Year Change | 3899.02% |
| Growth Volatility | 228.8 |
Diaceutics PLC - Net Assets Trend (2015–2025)
This chart illustrates how Diaceutics PLC's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see DXRX market cap.
Annual Net Assets for Diaceutics PLC (2015–2025)
The table below shows the annual net assets of Diaceutics PLC from 2015 to 2025. Also explore DXRX year-over-year net asset growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | GBX40.48 Million ≈ $4.93K |
+1.56% |
| 2024-12-31 | GBX39.86 Million ≈ $4.85K |
-2.28% |
| 2023-12-31 | GBX40.79 Million ≈ $4.96K |
-4.06% |
| 2022-12-31 | GBX42.51 Million ≈ $5.17K |
+4.59% |
| 2021-12-31 | GBX40.65 Million ≈ $4.95K |
+1.02% |
| 2020-12-31 | GBX40.24 Million ≈ $4.90K |
+99.87% |
| 2019-12-31 | GBX20.13 Million ≈ $2.45K |
+665.64% |
| 2018-12-31 | GBX2.63 Million ≈ $319.93 |
+40.03% |
| 2017-12-31 | GBX1.88 Million ≈ $228.47 |
+85.50% |
| 2016-12-31 | GBX1.01 Million ≈ $123.16 |
+507.18% |
| 2015-12-31 | GBX166.71K ≈ $20.28 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Diaceutics PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4164431200.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | GBX41.60 Million | 102.77% |
| Common Stock | GBX170.00K | 0.42% |
| Other Comprehensive Income | GBX-980.00K | -2.42% |
| Total Equity | GBX40.48 Million | 100.00% |
Diaceutics PLC Competitors by Market Cap
The table below lists competitors of Diaceutics PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FAT Brands Inc
NASDAQ:FATBB
|
$1.65 Million |
|
Capella Minerals Ltd
V:CMIL
|
$1.66 Million |
|
Current Water Technologies Inc
V:WATR
|
$1.66 Million |
|
Smtrack Bhd
KLSE:0169
|
$1.66 Million |
|
Jaguar Animal Health Inc
NASDAQ:JAGX
|
$1.65 Million |
|
Fsport AB
ST:FSPORT
|
$1.65 Million |
|
Apogee Minerals Ltd
V:APMI
|
$1.64 Million |
|
NEVADA SUNRISE METALS
F:K4L
|
$1.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Diaceutics PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 39,857,000 to 40,480,000, a change of 623,000 (1.6%).
- Net income of 97,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 354,000.
- Other factors increased equity by 880,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX97.00K | +0.24% |
| Other Comprehensive Income | GBX-354.00K | -0.87% |
| Other Changes | GBX880.00K | +2.17% |
| Total Change | GBX- | 1.56% |
Book Value vs Market Value Analysis
This analysis compares Diaceutics PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 336.47x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 25893.76x to 336.47x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | GBX0.01 | GBX160.00 | x |
| 2016-12-31 | GBX0.01 | GBX160.00 | x |
| 2017-12-31 | GBX0.03 | GBX160.00 | x |
| 2018-12-31 | GBX0.04 | GBX160.00 | x |
| 2019-12-31 | GBX0.31 | GBX160.00 | x |
| 2020-12-31 | GBX0.52 | GBX160.00 | x |
| 2021-12-31 | GBX0.48 | GBX160.00 | x |
| 2022-12-31 | GBX0.49 | GBX160.00 | x |
| 2023-12-31 | GBX0.48 | GBX160.00 | x |
| 2024-12-31 | GBX0.47 | GBX160.00 | x |
| 2025-12-31 | GBX0.48 | GBX160.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Diaceutics PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.24%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.25%
- • Asset Turnover: 0.77x
- • Equity Multiplier: 1.24x
- Recent ROE (0.24%) is below the historical average (6.23%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -62.08% | -7.40% | 1.04x | 8.05x | GBX-120.16K |
| 2016 | 73.81% | 16.28% | 1.33x | 3.40x | GBX645.91K |
| 2017 | 35.32% | 9.00% | 1.34x | 2.92x | GBX475.42K |
| 2018 | 24.05% | 6.10% | 1.33x | 2.97x | GBX369.36K |
| 2019 | 1.98% | 2.96% | 0.60x | 1.11x | GBX-1.62 Million |
| 2020 | 0.65% | 2.07% | 0.29x | 1.08x | GBX-3.76 Million |
| 2021 | 1.38% | 4.02% | 0.31x | 1.11x | GBX-3.50 Million |
| 2022 | 1.70% | 3.71% | 0.40x | 1.14x | GBX-3.53 Million |
| 2023 | -4.28% | -7.37% | 0.51x | 1.14x | GBX-5.82 Million |
| 2024 | -4.27% | -5.30% | 0.66x | 1.22x | GBX-5.69 Million |
| 2025 | 0.24% | 0.25% | 0.77x | 1.24x | GBX-3.95 Million |
Industry Comparison
This section compares Diaceutics PLC's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $26,185,360
- Average return on equity (ROE) among peers: 12.40%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Diaceutics PLC (DXRX) | GBX40.48 Million | -62.08% | 0.24x | $1.65 Million |
| Cambridge Cognition Holdings Plc (COG) | $632.00K | 71.20% | 18.84x | $158.60K |
| Craneware Plc (CRW) | $59.84 Million | 25.04% | 0.78x | $5.57 Million |
| Feedback PLC (FDBK) | $10.87 Million | -26.85% | 0.08x | $36.52K |
| Induction Healthcare Group PLC (INHC) | $16.47 Million | -46.24% | 0.22x | $111.33K |
| IQ-AI Ltd (IQAI) | $4.13 Million | 76.23% | 2.71x | $24.76K |
| Kooth plc (KOO) | $-1.76 Million | 0.00% | 0.00x | $816.86K |
| Optima Health plc (OPT) | $126.31 Million | -0.19% | 0.52x | $3.26 Million |
| Renalytix AI plc (RENX) | $-7.00 Million | 0.00% | 0.00x | $316.38K |
About Diaceutics PLC
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, that en… Read more